Skip to main content
Top
Published in: Endocrine 3/2014

01-12-2014 | Viewpoint

Ultrasonography, FNA, mutations, hormones and thyroid nodule obsession in the twenty-first century: a cytopathologist’s plea for reason in the age of thyroid storm

Author: Vicki J. Schnadig

Published in: Endocrine | Issue 3/2014

Login to get access

Excerpt

Once, the physician had only observing eyes, listening ears, skilled fingers and the humble stethoscope. Then, came the roentgenogram and limited use of the ultrasound machine [1]. Next came computerized tomography (CT), high-resolution imaging and a bourgeoning use of thyroid ultrasonography (US) instigated by CT, MRI and carotid screening incidentalomas. This US explosion has led us to a new overwhelming question. Is it good? Thyroid US-related publications have amplified from 7 in 1965–1970, to over 600 in the early 2000’s [1]. A 2014 PubMed search of “ultrasonography of the thyroid” yields more than 6,000 titles. This amount of publications is minuscule compared to the number of thyroid ultrasound examinations and US-guided FNA performed yearly. Radiologists, endocrinologists, otolaryngologists, surgeons and pathologists wield US machines and FNA needles. Will thyroid US screening and FNA soon be offered at our local shopping malls? Guidelines do not support generalized US thyroid screening [2]; however, referral of incidentalomas for US is recommended [2, 3]. In 2010, we compared our institute’s thyroid FNA performed in 1997–1998 with those performed in 2009–2010 [4] (see Table 1). During the 97–98 years, thyroid FNA (256) represented 9 % (256/2718) of our total FNA, and only 7 % were performed under US; thus, most nodules were palpable. Only 2 (1 %) of patients had multiple sites aspirated although 22 had repeat FNA. In the 2009–2010 years, 205 patients had thyroid FNA. Thyroid composed 22 % of our total FNA (281/1269). Concomitantly, our 2009–2010/1997–1998 ratios for lung (112/270) and lymph node or soft tissue FNA (472/1003) markedly decreased. In 2009–2010, 96 % of thyroid FNA were performed under US, and 68 (33 %) of the 205 patients had 2 or 3 nodules aspirated. In 2011, our total non-thyroid FNA decreased further and thyroid FNA rate was 32 %. An upward age trend was also found. In the 1997–1998 years, 40 % were older than 50 years increasing to 60 % in 2009–2010. How many of these were incidentalomas? Stringently defined as nodules found on imaging of patients without past history of hypothyroidism, palpable nodules or signs or symptoms potentially related to thyroid, 83/205 (40 %) patients had FNA for incidentalomas. The reasons for discovery included: CT for non-thyroid mass or cancer (19), CT, angiogram or MRI for pain, trauma. (34), health fair (4) and miscellaneous other reasons (26). Ten (12 %) of the incidentalomas were resected. Five (50 %) were adenomas, and five (50 %) non-neoplastic benign. None were clinically aggressive papillary carcinomas; however, two incidental micropapillary carcinomas were found within benign lesions.
Table 1
Thyroid FNA data, 1997–1998 versus 2009–2010
 
1997–1998
2009–2010
Thyroid FNA total FNA
256/2718 (9 %)
281/1269 (22 %)
Total thyroid FNA patients (Pts)
232
205
Mean age (% >50 years)
46 (40 %)
53 (60 %)
Total soft tissue or lymph node FNA
1003
472
Total lung FNA
270
112
Pts with thyroid incidentalomas/total thyroid FNA pts
NA
83/205 (40 %)
Pts with resected incidentalomas/total incidentaloma pts
NA
10/83 (12 %)
Incidentaloma adenoma/total resected
NA
5/10 (50 %)
Incidentaloma micropapillary carcinoma/total resected
NA
2/10 (20 %)
Incidentaloma aggressive carcinoma
NA
0
Literature
1.
go back to reference R.A. Levine, Something old and something new: a brief history of thyroid ultrasound technology. Endocr. Pract. 10, 227–233 (2004)PubMedCrossRef R.A. Levine, Something old and something new: a brief history of thyroid ultrasound technology. Endocr. Pract. 10, 227–233 (2004)PubMedCrossRef
2.
go back to reference H. Gharib, E. Papini, R. Paschke et al., American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J. Endocrinol. Invest. 33, 287–291 (2010)PubMedCrossRef H. Gharib, E. Papini, R. Paschke et al., American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J. Endocrinol. Invest. 33, 287–291 (2010)PubMedCrossRef
3.
go back to reference D.S. Cooper, G.M. Doherty, B.R. Haugen et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)PubMedCrossRef D.S. Cooper, G.M. Doherty, B.R. Haugen et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)PubMedCrossRef
4.
go back to reference V.J. Schnadig, M. Kathuria, The changing panorama of thyroid FNA; is change good? Poster presentation; 101st annual meeting of United States and Canadian Academy of Pathology, Vancouver, British Columbia, Canada, March 17–23, 2012. Mod. Pathol. 27, 150A (2012) V.J. Schnadig, M. Kathuria, The changing panorama of thyroid FNA; is change good? Poster presentation; 101st annual meeting of United States and Canadian Academy of Pathology, Vancouver, British Columbia, Canada, March 17–23, 2012. Mod. Pathol. 27, 150A (2012)
5.
go back to reference P.T. Johnson, K.M. Horton, A.J. Megaibow, R.B. Jeffrey, E.K. Fishman, Common incidental findings on MDCT: survey of radiologist recommendations for patient management. J. Am. Coll. Radiol. 8, 762–767 (2011)PubMedCrossRef P.T. Johnson, K.M. Horton, A.J. Megaibow, R.B. Jeffrey, E.K. Fishman, Common incidental findings on MDCT: survey of radiologist recommendations for patient management. J. Am. Coll. Radiol. 8, 762–767 (2011)PubMedCrossRef
6.
7.
go back to reference F. Pacini, Management of papillary thyroid microcarcinoma: primum non nocere! J. Clin. Endocrinol. Metab. 98, 1391–1393 (2013)PubMedCrossRef F. Pacini, Management of papillary thyroid microcarcinoma: primum non nocere! J. Clin. Endocrinol. Metab. 98, 1391–1393 (2013)PubMedCrossRef
8.
go back to reference J.J. Cronan, Thyroid nodules: is it time to turn off the ultrasound machines? Radiology 247, 602–604 (2008)PubMedCrossRef J.J. Cronan, Thyroid nodules: is it time to turn off the ultrasound machines? Radiology 247, 602–604 (2008)PubMedCrossRef
9.
go back to reference D.S. Ross, Editorial: nonpalpable thyroid nodules—managing an epidemic. J. Clin. Endocrinol. Metab. 87, 1938–1940 (2002)PubMed D.S. Ross, Editorial: nonpalpable thyroid nodules—managing an epidemic. J. Clin. Endocrinol. Metab. 87, 1938–1940 (2002)PubMed
10.
11.
go back to reference R.T. Vollmer, Revisiting overdiagnosis and fatality in thyroid cancer. Am. J. Clin. Pathol. 141, 128–132 (2014)PubMedCrossRef R.T. Vollmer, Revisiting overdiagnosis and fatality in thyroid cancer. Am. J. Clin. Pathol. 141, 128–132 (2014)PubMedCrossRef
12.
go back to reference L.G.T. Morris, A.G. Sikora, T.D. Tosteson, L. Davies, The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 23, 885–891 (2013)PubMedCentralPubMedCrossRef L.G.T. Morris, A.G. Sikora, T.D. Tosteson, L. Davies, The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 23, 885–891 (2013)PubMedCentralPubMedCrossRef
13.
go back to reference J. Yang, V. Schnadig, R. Logroño, P.G. Wasserman, Fine needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer Cytopathol. 111, 306–315 (2007)CrossRef J. Yang, V. Schnadig, R. Logroño, P.G. Wasserman, Fine needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer Cytopathol. 111, 306–315 (2007)CrossRef
14.
go back to reference R.M. DeMay, Follicular lesions of the thyroid. W(h)ither follicular carcinoma? Am. J. Clin. Pathol. 114, 681–683 (2000)PubMedCrossRef R.M. DeMay, Follicular lesions of the thyroid. W(h)ither follicular carcinoma? Am. J. Clin. Pathol. 114, 681–683 (2000)PubMedCrossRef
15.
go back to reference E.S. Cibas, S.Z. Ali, The Bethesda system for reporting thyroid cytopathology. Am. J. Clin. Pathol. 132, 158–165 (2009)CrossRef E.S. Cibas, S.Z. Ali, The Bethesda system for reporting thyroid cytopathology. Am. J. Clin. Pathol. 132, 158–165 (2009)CrossRef
16.
go back to reference W.C. Black, H.G. Welch, Advances in diagnostic images and overestimations of disease prevalence and benefits of therapy. N. Engl. J. Med. 328, 1237–1243 (1993)PubMedCrossRef W.C. Black, H.G. Welch, Advances in diagnostic images and overestimations of disease prevalence and benefits of therapy. N. Engl. J. Med. 328, 1237–1243 (1993)PubMedCrossRef
18.
go back to reference I. Sugitani, K. Toda, K. Yamada et al., Three distinctly different kinds of papillary thyroid micropapillary carcinoma should be recognized: our treatment strategies and outcomes. World J. Surg. 34, 1222–1231 (2010)PubMedCrossRef I. Sugitani, K. Toda, K. Yamada et al., Three distinctly different kinds of papillary thyroid micropapillary carcinoma should be recognized: our treatment strategies and outcomes. World J. Surg. 34, 1222–1231 (2010)PubMedCrossRef
19.
go back to reference Y. Ito, T. Uruno, K. Nakano et al., An observational trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13, 381–387 (2003)PubMedCrossRef Y. Ito, T. Uruno, K. Nakano et al., An observational trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13, 381–387 (2003)PubMedCrossRef
20.
go back to reference H.R. Harach, K.O. Franssila, V.-M. Wasenius, Occult papillary carcinoma of the thyroid a “normal” finding in Finland. A systemic autopsy study. Cancer 56, 531–538 (1985)PubMedCrossRef H.R. Harach, K.O. Franssila, V.-M. Wasenius, Occult papillary carcinoma of the thyroid a “normal” finding in Finland. A systemic autopsy study. Cancer 56, 531–538 (1985)PubMedCrossRef
21.
go back to reference L.A. Valle, R.T. Kloos, The prevalence of occult medullary thyroid carcinoma at autopsy. J. Clin. Endocrinol. Metab. 96, E109–E113 (2011)PubMedCrossRef L.A. Valle, R.T. Kloos, The prevalence of occult medullary thyroid carcinoma at autopsy. J. Clin. Endocrinol. Metab. 96, E109–E113 (2011)PubMedCrossRef
22.
go back to reference P. Trimboli, L. Guidobaldi, A. Crecenze, M. Bongiovanni, L. Giovanella, The essential use of FNA-calcitonin for detecting medullary thyroid cancer. Endocrine (2014). doi:10.1007/s12020-014-0226-x P. Trimboli, L. Guidobaldi, A. Crecenze, M. Bongiovanni, L. Giovanella, The essential use of FNA-calcitonin for detecting medullary thyroid cancer. Endocrine (2014). doi:10.​1007/​s12020-014-0226-x
23.
go back to reference Y. Ito, A. Miyauchi, K. Kobayashi, A. Miya, Prognosis and growth activity depend on patient age in clinical and subclinical papillary thyroid carcinoma. Endocrinol. J. (2013). doi:10.1507/endocrj.EJ13-0403 Y. Ito, A. Miyauchi, K. Kobayashi, A. Miya, Prognosis and growth activity depend on patient age in clinical and subclinical papillary thyroid carcinoma. Endocrinol. J. (2013). doi:10.​1507/​endocrj.​EJ13-0403
24.
go back to reference Y. Ito, H. Yoshida, M. Kihara et al., BRAFV600E mutation analysis in papillary carcinoma: is it useful for all patients? World J. Surg. 38, 679–687 (2014)PubMedCrossRef Y. Ito, H. Yoshida, M. Kihara et al., BRAFV600E mutation analysis in papillary carcinoma: is it useful for all patients? World J. Surg. 38, 679–687 (2014)PubMedCrossRef
25.
go back to reference C. Li, P.H. Aragon, K.C. Lee et al., Does BRAFV600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J. Clin. Endocrinol. Metab. 98, 3702–3712 (2013)PubMedCrossRef C. Li, P.H. Aragon, K.C. Lee et al., Does BRAFV600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J. Clin. Endocrinol. Metab. 98, 3702–3712 (2013)PubMedCrossRef
26.
go back to reference C. Gouveia, N.T. Can, A. Bostrom, J.P. Grenert, A. van Zante, L.A. Orloff, Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma the University of California, San Francisco experience. JAMA Otolaryngol. Head Neck Surg. 139, 1164–1170 (2013)PubMedCrossRef C. Gouveia, N.T. Can, A. Bostrom, J.P. Grenert, A. van Zante, L.A. Orloff, Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma the University of California, San Francisco experience. JAMA Otolaryngol. Head Neck Surg. 139, 1164–1170 (2013)PubMedCrossRef
27.
go back to reference B.J. Vazquez, M.L. Richards, Imaging of the thyroid and parathyroid glands. Surg. Clin. N. Am. 91, 15–32 (2011)PubMedCrossRef B.J. Vazquez, M.L. Richards, Imaging of the thyroid and parathyroid glands. Surg. Clin. N. Am. 91, 15–32 (2011)PubMedCrossRef
Metadata
Title
Ultrasonography, FNA, mutations, hormones and thyroid nodule obsession in the twenty-first century: a cytopathologist’s plea for reason in the age of thyroid storm
Author
Vicki J. Schnadig
Publication date
01-12-2014
Publisher
Springer US
Published in
Endocrine / Issue 3/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0322-y

Other articles of this Issue 3/2014

Endocrine 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.